Experience in the intravenous solutions market and a solid commitment to quality make Grifols Partnership a reliable and efficient strategic partner for your contract manufacturing needs.
Our high level of specialization allows us to offer pharmaceutical development and manufacturing for products that require advanced technology and complex production processes such sterile solutions and lipid emulsions.
Grifols Partnership has two FDA and GMP approved manufacturing facilities in Spain for intravenous solutions that have parametric release certification.
Grifols Partnership works together with the customer from the early stages of development to commercial manufacturing industrial batches.
• Pre-formulation and development
• Scale-up and technology transfer of methods
• Validation batches
• Process scale-up and pilot production including 10/300L reactors
• ICH stability studies
• Analytical development and validation
• Clinical batches
• Dossier support documentation
• Commercial manufacturing of industrial batches
• Labelling and packaging
Technological capabilities:
• Aqueous (LVP & SVP)
• Diluents for reconstitution
• Emulsion technology
• Form Fill Seal (FFS) technology for PP bags
• Manufacture and filling of oxygen and light sensitive products
• Terminal sterilization
Container Technologies
• Vials: 5ml to 50ml, glass and plastic
• Glass Bottles: 50ml to 500ml
• Flexible Polypropylene IV Bags: 50ml to 3000ml
Contact details :
Grifols International, S.A.
E-mail: marga.vines@grifols.com
Website: www.partnership.grifols.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.